Zoetis Inc. logo

Zoetis Inc. 0M3Q

Market Closed
19 Sep, 15:30
LSE LSE
$
197. 31
-0.01
-0.01%
$
68.94B Market Cap
29.76 P/E Ratio
1.73% Div Yield
7,920 Volume
5.79 Eps
$ 197.32
Previous Close
Day Range
197.31 200.19
Year Range
144.82 201.92

0M3Q Chart

Zoetis Inc. Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Ms. Kristin C. Peck CEO
LSE Exchange
US98978V1035 ISIN
US Country
14,100 Employees
18 Jul 2024 Last Dividend
- Last Split
1 Feb 2013 IPO Date
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Contact Information

Address: 10 Sylvan Way, Parsippany, NJ, United States, 07054
Phone: 973 822 7000